Actuate Therapeutics, Inc. – Material Contracts Watch

from 8-K 8 pages Form of Registration Rights Agreement

from 8-K 27 pages Form of Securities Purchase Agreement

from 10-Q 3 pages First Amendment to Employment Agreement

from 10-Q 2 pages First Amendment to Employment Agreement

from 10-Q 3 pages Tenth Amendment to Employment Agreement

from 8-K 25 pages Registration Rights Agreement

from 8-K 85 pages Common Stock Purchase Agreement Dated as of March 27, 2025 by and Between Actuate Therapeutics, Inc. and B. Riley Principal Capital II, LLC

from 10-Q 2 pages Actuate Therapeutics, Inc. Non-Employee Director Compensation Program

from S-1/A 30 pages Exclusive License Agreement With Equity

from S-1/A 3 pages Actuate Therapeutics, Inc. Non-Employee Director Compensation Program

from S-1/A 6 pages Actuate Therapeutics, Inc. 2024 Stock Incentive Plan Restricted Stock Unit Grant Notice

from S-1/A 7 pages Actuate Therapeutics, Inc. 2024 Stock Incentive Plan Stock Option Grant Notice

from S-1/A 57 pages Employment Agreement

from S-1/A 3 pages Actuate Therapeutics, Inc. Non-Employee Director Compensation Program

from S-1 18 pages Actuate Therapeutics, Inc. Indemnification Agreement

from S-1 16 pages Actuate Therapeutics, Inc. Indemnification Agreement

from S-1 7 pages Form of Indemnification Agreement

from S-1 24 pages This Employment Agreement (This “Agreement”), Is Entered Into to Be Effective as of June 1, 2024 (The “Effective Date”), by and Between Actuate Therapeutics, Inc., a Delaware Corporation (The “Company”), and Paul Lytle, an Individual Currently Residing at [●] (The “Employee”). Whereas, Company Desires to Employ the Employee on the Terms, Conditions and for the Consideration Hereinafter Set Forth, and the Employee Is Willing to Serve as an Employee of the Company on Such Terms and Conditions and for Such Consideration. Now Therefore, for and in Consideration of the Mutual Promises, Covenants and Obligations Contained Herein, the Company and the Employee Hereby Agree as Follows

from S-1 8 pages You and Actuate Therapeutics, Inc. (The “Company”) Have Had Discussions Concerning Your Desire to Render Professional Consulting Services to the Company as Described Herein. the Company Wants to Engage Your Services, and You Want to Render Them, Subject to the Terms and Conditions of This Letter Agreement (This “Agreement”), Which Shall Become Effective Upon the Last Date of Signature of This Agreement by Both Parties (The “Effective Date”). for the Purpose of This Agreement, You Shall Be Referred to Herein as “Consultant.”

from S-1 14 pages This Employment Agreement (This “Agreement”), Is Entered Into to Be Effective as of June 1, 2022 (The “Effective Date”), by and Between Actuate Therapeutics, Inc., a Delaware Corporation (The “Company”), and Andrew Mazar, an Individual Currently Residing at [***], (The “Executive”). Whereas, Company Desires to Employ the Executive on the Terms, Conditions and for the Consideration Hereinafter Set Forth, and the Executive Is Willing to Serve as an Employee of the Company on Such Terms and Conditions and for Such Consideration. Now Therefore, for and in Consideration of the Mutual Promises, Covenants and Obligations Contained Herein, the Company and the Executive Hereby Agree as Follows